register

News & Trends - MedTech & Diagnostics

Greater reliance on hospital sector raises policy issues

Health Industry Hub | December 8, 2021 |

MedTech News: Australia’s healthcare system is one of the best in the western world when it comes to patient outcomes following hip fracture or heart disease, a new study reveals.

The International Collaborative on Costs, Outcomes and Needs in Care (ICCONIC) study, led by Harvard University and the London School of Economics, compared healthcare costs and death rates across similar patient groups in 10 OECD countries. The Centre for Health Economics Research and Evaluation (CHERE) at the University of Technology Sydney conducted the Australian arm of the research. A special issue of the Health Services Research journal recently published a series of papers on the results.

Deputy Director of CHERE, Professor Kees Van Gool, said comparing how other health care systems look after high-need patients can provide important insights on how each country’s health system performs. 

“International comparisons of health care costs, use, access and outcomes allows policy makers to benchmark and measure improvements in health system performance. A comparative analysis can also identify where improved performance could lead to better health outcomes and a more sustainable system,” said Professor Van Gool.

In order to assess health outcomes, the study focused on two groups of patients aged over 65 – people admitted to hospital with heart failure who have diabetes, and those who had hip replacement surgery due to a hip fracture.

Australia had the lowest one-year mortality rate for patients with chronic heart failure and the second lowest mortality rate for patients with a hip fracture.

Following hospitalisation due to heart failure with diabetes, 22% of patients in Australia had died of any cause after one year, while England had the highest rate at 43%. 

A year after hip replacement surgery 21% of patients in Australia had died, with only France having a lower rate at 20%. England had the highest rate with nearly one third of patients not surviving the first year.

The researchers used data from 2014 to 2018, so the study did not include the impact of COVID-19 on health outcomes. Australia’s contribution to the study was based on NSW data.

“Compared to other countries, Australia spends relatively little on primary care and relatively more on hospital care, however the lower cost of primary care was due to lower fees rather than fewer visits to the GP,” said Professor Van Gool.

“Australian patients in the study were admitted to hospital more often than comparable patients in other countries but they had relatively shorter lengths of stay. The cost per hospitalisation in Australia was high compared to other countries.

“This greater reliance on the hospital sector raises some interesting policy issues on the stronger role that primary care could play in managing patients with complex conditions,” he said.

Australia and New Zealand reported a very low percentage of people dying in hospital. Australian patients were admitted fewer times in the last 12 months of life than patients residing in other countries.

In contrast to countries like the US and Germany, primary care physicians also took a greater role in end-of-life care in Australia.

The study also compared the use of prescription drugs and the price per script. The degree of variation across countries was quite low, with the notable exception of the US, whose citizens pay a much higher price per script.  


Medical

NSW Health to settle class action

NSW Health to settle ‘largest’ class action

Health Industry Hub | April 29, 2024 |

A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]

More


News & Trends - Pharmaceuticals

Lilly's first-in-class therapy PBS listed for early breast cancer after 15-year gap

Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap

Health Industry Hub | April 29, 2024 |

Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]

More


News & Trends - Pharmaceuticals

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

Health Industry Hub | April 29, 2024 |

Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]

More


News & Trends - Pharmaceuticals

PBAC recommendation to reshape prescribing in heart failure

PBAC recommendation to reshape prescribing in heart failure

Health Industry Hub | April 29, 2024 |

Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]

More


This content is copyright protected. Please subscribe to gain access.